168 related articles for article (PubMed ID: 402652)
21. [Sphingolipidoses. Biochemistry and enzymatic mechanisms].
Gajdos A
Nouv Presse Med; 1972 Jun; 1(26):1789-92. PubMed ID: 5054020
[No Abstract] [Full Text] [Related]
22. Molecular facets of sphingolipids: mediators of diseases.
Ozbayraktar FB; Ulgen KO
Biotechnol J; 2009 Jul; 4(7):1028-41. PubMed ID: 19579220
[TBL] [Abstract][Full Text] [Related]
23. [Biochemical aspects of sphingolipidosis].
Douste-Blazy L; Thouvenot JP
Ann Biol Clin (Paris); 1972; 30(6):623-35. PubMed ID: 4569435
[No Abstract] [Full Text] [Related]
24. Characterization of neutral and acidic glycosphingolipids in brains of two patients with GM1 gangliosidosis type 1 and type 2.
Ishikawa Y; Makita A; Minami R
J Neurochem; 1985 Apr; 44(4):1100-6. PubMed ID: 3919156
[TBL] [Abstract][Full Text] [Related]
25. Lipid storage disease: Part III. Ultrastructural evaluation of cultured fibroblasts in sphingolipidoses.
Takahashi K; Naito M; Suzuki Y
Acta Pathol Jpn; 1987 Feb; 37(2):261-72. PubMed ID: 3037847
[TBL] [Abstract][Full Text] [Related]
26. Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease.
Paciotti S; Albi E; Parnetti L; Beccari T
J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32098196
[TBL] [Abstract][Full Text] [Related]
27. Therapy for the sphingolipidoses.
Brady RO
Arch Neurol; 1998 Aug; 55(8):1055-6. PubMed ID: 9708954
[TBL] [Abstract][Full Text] [Related]
28. Lysosomal Glycosphingolipid Storage Diseases.
Breiden B; Sandhoff K
Annu Rev Biochem; 2019 Jun; 88():461-485. PubMed ID: 31220974
[TBL] [Abstract][Full Text] [Related]
29. My journey into the world of sphingolipids and sphingolipidoses.
Sandhoff K
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(10):554-82. PubMed ID: 23229750
[TBL] [Abstract][Full Text] [Related]
30. Rare Diseases in Glycosphingolipid Metabolism.
Zhou H; Wu Z; Wang Y; Wu Q; Hu M; Ma S; Zhou M; Sun Y; Yu B; Ye J; Jiang W; Fu Z; Gong Y
Adv Exp Med Biol; 2022; 1372():189-213. PubMed ID: 35503182
[TBL] [Abstract][Full Text] [Related]
31. Neuronal sphingolipidoses: Membrane lipids and sphingolipid activator proteins regulate lysosomal sphingolipid catabolism.
Sandhoff K
Biochimie; 2016 Nov; 130():146-151. PubMed ID: 27157270
[TBL] [Abstract][Full Text] [Related]
32. GM2-ganglioside metabolism in cultured human skin fibroblasts: unambiguous diagnosis of GM2-gangliosidosis.
Raghavan S; Krusell A; Lyerla TA; Bremer EG; Kolodny EH
Biochim Biophys Acta; 1985 Apr; 834(2):238-48. PubMed ID: 3995063
[TBL] [Abstract][Full Text] [Related]
33. Sphingolipids and neuronal degeneration in lysosomal storage disorders.
Grassi S; Chiricozzi E; Mauri L; Sonnino S; Prinetti A
J Neurochem; 2019 Mar; 148(5):600-611. PubMed ID: 29959861
[TBL] [Abstract][Full Text] [Related]
34. The biochemistry of sphingolipid storage diseases.
Sandhoff K
Angew Chem Int Ed Engl; 1977 May; 16(5):273-85. PubMed ID: 406814
[No Abstract] [Full Text] [Related]
35. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases.
Puri V; Watanabe R; Dominguez M; Sun X; Wheatley CL; Marks DL; Pagano RE
Nat Cell Biol; 1999 Oct; 1(6):386-8. PubMed ID: 10559968
[No Abstract] [Full Text] [Related]
36. Brain ceramide hexosides in Tay-Sachs disease and generalized gangliosidosis (GM1-gangliosidosis).
Suzuki K; Chen GC
J Lipid Res; 1967 Mar; 8(2):105-13. PubMed ID: 14564716
[TBL] [Abstract][Full Text] [Related]
37. Chemical compositions of brain and myelin in two patients with multiple sulphatase deficiency (a variant form of metachromatic leukodystrophy).
Eto Y; Meier C; Herschkowitz NN
J Neurochem; 1976 Nov; 27(5):1071-6. PubMed ID: 12170590
[TBL] [Abstract][Full Text] [Related]
38. Composition of gangliosides and neutral glycosphingolipids of brain in classical Tay-Sachs and Sandhoff disease: more lyso-GM2 in Sandhoff disease?
Rosengren B; Månsson JE; Svennerholm L
J Neurochem; 1987 Sep; 49(3):834-40. PubMed ID: 3612128
[TBL] [Abstract][Full Text] [Related]
39. Neutral glycosphingolipids and gangliosides of bovine thyroid.
Iwamori M; Sawada K; Hara Y; Nishio M; Fujisawa T; Imura H; Nagai Y
J Biochem; 1982 Jun; 91(6):1875-87. PubMed ID: 7118850
[TBL] [Abstract][Full Text] [Related]
40. Tissue accumulation of sulfatide and GM3 ganglioside in a patient with variant Farber disease.
Fujiwaki T; Hamanaka S; Tate S; Inagaki F; Suzuki M; Suzuki A; Mori C
Clin Chim Acta; 1995 Jan; 234(1-2):23-36. PubMed ID: 7758220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
